Development Pipeline (as of February 1, 2012)
Development Pipeline [
73KB]
73KB]Oncology
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG435 | Breast cancer * | Approved Sep.11 |
bevacizumab Avastin® Injection |
Roche Avastin® |
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody |
| Gastric cancer * | Phase III | ||||
| Breast cancer (adjuvant) * |
Phase III Multinational study |
||||
| Glioblastoma * | Phase III Multinational study |
||||
| Glioblastoma (relapsed) * | Phase II | ||||
| EPOCH | Chemotherapy-induced anemia * | - | epoetin beta Epogin® Injection |
In-house | Recombinant human erythropoietin |
| RG1273 | Breast cancer | Phase III Multinational study |
pertuzumab Injection |
Roche | Humanized HER dimerization inhibitory monoclonal antibody |
| RG3502 | Breast cancer | Phase III Multinational study |
Injection |
Roche | HER2 antibody-drug conjugate (T-DM1) |
| GA101 (RG7159) |
Indolent NHL | Phase III Multinational study |
obinutuzumab Injection |
Roche | Humanized anti-CD20 monoclonal antibody |
| Aggressive NHL | Phase III Multinational study |
||||
| RG1415 | Non-small cell lung cancer (1st line) * | Phase II | erlotinib HCl Tarceva® Oral |
Roche / OSI Tarceva® |
EGFR tyrosine kinase inhibitor |
| MRA | Pancreatic cancer * | Phase I / II | tocilizumab Actemra® Injection |
In-house |
Humanized anti-human IL-6 receptor monoclonal antibody |
| AF802 | Non-small cell lung cancer | Phase I / II | Oral |
In-house |
ALK inhibitor |
| WT4869 | Myelodysplastic syndromes | Phase I / II | Injection |
In-house / Dainippon Sumitomo Pharma | WT1 peptide cancer vaccine |
| Solid tumors | Phase I | ||||
| CIF (RG7167) |
Solid tumors | Phase I | Oral |
In-house (Roche) |
MEK inhibitor |
| Phase I Overseas |
|||||
| CKI27 (RG7304) |
Solid tumors | Phase I | Oral |
In-house (Roche) |
Raf and MEK dual inhibitor |
| Phase I Overseas |
|||||
| GC33 (RG7686) |
Liver cancer | Phase I | Injection |
In-house (Roche) |
Humanized anti-Glypican-3 monoclonal antibody |
| Phase I Overseas | |||||
| PA799 | Solid tumors | Phase I Overseas | Oral |
In-house | PI3K class I inhibitor |
| RG3638 | Non-small cell lung cancer | Phase I | Injection |
Roche | Humanized anti-Met antibody |
Bone and Joint Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| MRA | Systemic-onset juvenile idiopathic arthritis (sJIA) * | Approved Aug.11 EU |
tocilizumab Actemra® / RoActemra®(EU) Injection |
In-house (Roche) |
Humanized anti-human IL-6 receptor monoclonal antibody |
| Rheumatoid arthritis (new formulation : subcutaneous injection) | Phase III | ||||
| Phase III Overseas | |||||
| NRD101 | Enthesopathy (Lateral epicondylitis, Patellar tendinitis, Achilles tendinopathy, Plantar fasciitis) |
Phase III | sodium hyaluronate Suvenyl® Injection |
In-house | Sodium hyaluronate |
| RG484 | Osteoporosis | Phase II / III | ibandronate sodium hydrate Injection |
Roche Boniva® (US) / Bonviva® (EU) (Taisho Pharmaceutical) |
Bisphosphonate |
| Phase II | ibandronate sodium hydrate Oral |
||||
| SA237 | Rheumatoid arthritis | Phase I | Injection |
In-house | Humanized anti-human IL-6 receptor monoclonal antibody |
Transplant, Immunology and Infectious Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG442 | Chronic hepatitis B * | Approved Sep.11 |
peginterferon alfa-2a Pegasys® Injection |
Roche Pegasys® |
Peginterferon alfa-2a agent (recombinant) |
| RG7128 | Chronic hepatitis C | Development suspended |
mericitabine Oral |
Roche | Polymerase inhibitor |
Other Diseases
| Development code | Indication * Additional indication |
Stage (date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| CSG452 | Type II diabetes | Phase III | tofogliflozin hydrate Oral |
In-house |
SGLT2 inhibitor |
| RG1678 | Schizophrenia | Phase III Multinational study | bitopertin Oral |
Roche | Glycine reuptake inhibitor |
| RG1450 | Alzheimer's disease | Phase I | gantenerumab Injection |
Roche / Morphosys | Human anti-amyloid-beta monoclonal antibody |
| RG7090 | Major depressive disorder | Phase I Overseas |
Oral |
Roche | mGluR5 antagonist |
| RG3637 | Asthma | Phase I | lebrikizumab Injection |
Roche | Humanized anti-IL-13 antibody |
To view PDF files,
you will need Adobe® Reader® which is available as a free download.
